Infarto agudo de miocardio: tratamiento de la etapa hiperaguda

Trongé, Jorge; Villamayor, Rosa M.
Med. intensiva ; 6(4): 165-169, 1989.
Artículo en Español | LILACS | ID: lil-310125

Documentos relacionados

  1. The Role of Subretinal Injection in Ophthalmic Surgery: Therapeutic Agent Delivery and Other Indications.
  2. Alteplase and Thrombectomy - Not a Bridge to Dismantle.
  3. Reteplase versus Alteplase for Acute Ischemic Stroke.
  4. Factors influencing recanalization of thrombotic venous occlusions.
  5. In ischemic stroke, adding IV thrombolysis ≤2 h after symptom onset to thrombectomy was associated with benefit.
  6. An intelligent DNA nanodevice for precision thrombolysis.
  7. Improved visual outcomes of central retinal artery occlusion with local intra-arterial fibrinolysis beyond the conventional time window.
  8. Response by Agarwal et al to Letter Regarding Article, "Redefined Measure of Early Neurological Improvement Shows Treatment Benefit of Alteplase Over Placebo".
  9. A 5-Minute Delay From Bolus Injection to Infusion Halves Plasma Concentration of Tissue Plasminogen Activator.
  10. Multiphysics Modelling and Simulation of Thrombolysis via Activated Platelet-Targeted Nanomedicine.